Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Director | May 19, 2026 | May 21, 2026 |
| Vincerx Pharma, Inc.VINC · Entity 84409 | Director | May 23, 2024 | May 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,391 |
Reported balance
After 2026-05-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 665 · Balance 8,391 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. F2: These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.
F2: These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Vincerx Pharma, Inc.
Report date May 23, 2024 · Filed May 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2034-05-22 | Direct | 15,000 |
Reported balance
After 2024-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests in full on the earlier of May 23, 2025, the next annual meeting of stockholders, or the consummation of a change of control, subject to the director's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of May 23, 2025, the next annual meeting of stockholders, or the consummation of a change of control, subject to the director's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 21, 2026 22:57 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 665 | $0.00 | $0.00 |
DisclosureSEC source: 0000318154-26-000100 · form4.xml · nonDerivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,391 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 23, 2025 Filed May 29, 2025 00:58 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 809 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015850 · form4.xml · nonDerivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,569 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 417 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 23:25 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 719 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017807 · form4.xml · nonDerivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,472 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 471 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 23, 2024 Filed May 28, 2024 16:40 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0000950170-24-065299 · ownership.xml · derivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The option vests in full on the earlier of May 23, 2025, the next annual meeting of stockholders, or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| May 25, 2023 Filed May 30, 2023 16:05 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0000899243-23-014051 · doc4.xml · derivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-24 F1 · derivative.exercise_date: The option vests in full on the earlier of May 25, 2024, the next annual meeting of stockholders, or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| May 19, 2023 Filed May 23, 2023 23:19 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 939 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016633 · form4.xml · nonDerivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,688 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 406 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 26, 2022 Filed May 31, 2022 16:06 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0000899243-22-020149 · doc4.xml · derivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The option vests in full on the earlier of May 26, 2023, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| May 17, 2022 Filed May 20, 2022 01:52 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 855 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015173 · form4.xml · nonDerivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 257 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 18, 2021 Filed May 20, 2021 23:22 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 837 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-017697 · form4.xml · nonDerivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,634 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 146 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 13, 2021 Filed May 14, 2021 17:23 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $16.34 | $0.00 |
DisclosureSEC source: 0000899243-21-019559 · doc4.xml · derivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-12 F1 · derivative.exercise_date: The option vests in full on the earlier of May 13, 2022, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 21:24 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 6,667 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-035387 · doc4.xml · derivative · entry 2 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2030-12-23 F2 · derivative.exercise_date: The option vests in full on the earlier of December 23, 2021, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 21:24 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantCommon Stock | 54,806 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-035387 · doc4.xml · nonDerivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,806 F1 · price: Received pursuant to the Merger Agreement, dated as of September 25, 2020, by and among LifeSci Acquisition Corp. ("LifeSci"), Vincera Pharma, Inc. ("Legacy Vincera") and LifeSci Acquisition Merger Sub, Inc., a wholly-owned subsidiary of LifeSci ("Merger Sub"), pursuant to which Merger Sub merged with and into Legacy Vincera, with Legacy Vincera surviving the merger as a wholly-owned subsidiary of LifeSci (which subsequently changed its name to "Vincera Pharma, Inc."). Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:31 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 846 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-015846 · form4.xml · nonDerivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,719 F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 03, 2019 Filed May 7, 2019 22:16 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-017635 · form4.xml · nonDerivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,819 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 14 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 22:26 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 678 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024505 · form4.xml · nonDerivative · entry 1 Druker Brian · CIK 0001740205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.